Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03).
Plerixafor
Relapsed multiple myeloma
Salvage autologous transplant
Journal
Clinical hematology international
ISSN: 2590-0048
Titre abrégé: Clin Hematol Int
Pays: England
ID NLM: 101759455
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
01
11
2022
accepted:
11
01
2023
medline:
14
2
2023
pubmed:
14
2
2023
entrez:
13
2
2023
Statut:
ppublish
Résumé
Despite the implementation of new therapeutic agents, management of relapsed multiple myeloma (MM) remains a challenge. Salvage autologous hematopoietic cell transplant (AHCT) remains a valid therapeutic option for eligible patients who achieve prolonged response after a first AHCT. However, a second graft is not always available, and these patients may need a second mobilization. This prospective, non-interventional, multicenter study aimed to collect data on the feasibility of salvage AHCT using a plerixafor-based hematopoietic cell mobilization in relapsed MM, according to the plerixafor label in France. Adult patients with relapsed MM eligible for a second AHCT and mobilized using granulocyte- colony stimulating factor (G-CSF) and plerixafor were included. Of the 23 patients, 17 achieved a successful hematopoietic cell mobilization and 13 were able to proceed to a second AHCT. Median age was 62.9 years (min-max 51-71). Ten patients (77%) were male. Eleven (85%) received AHCT as a third-line treatment or more. Median time between first and second AHCT was 5.4 years (range, 2.6-16.3). Among 18 evaluable patients, mobilization was successful for 17 (94%) of them [95% CI 84-100], with no reported side effects. Among the 13 patients who underwent salvage AHCT, the median time to engraftment was 14 days (min-max 11-29). One-year progression-free and overall survival were 88.9% [95% CI 43.3-98.4] and 100%, respectively. This study demonstrated that plerixafor allows safe and efficient mobilization in relapsed MM patients who are candidates for a salvage AHCT. NCT02439476 Registered 8 May 2015, https://clinicaltrials.gov/ct2/show/NCT02439476 .
Identifiants
pubmed: 36781774
doi: 10.1007/s44228-023-00030-0
pii: 10.1007/s44228-023-00030-0
pmc: PMC9924840
doi:
Banques de données
ClinicalTrials.gov
['NCT02439476']
Types de publication
Journal Article
Langues
eng
Pagination
38-42Informations de copyright
© 2023. The Author(s).
Références
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8.
doi: 10.1038/leu.2013.313
pubmed: 24157580
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31.
doi: 10.1056/NEJMoa1607751
pubmed: 27705267
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–52.
doi: 10.1056/NEJMoa1411321
pubmed: 25482145
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021;32(3):309–22.
doi: 10.1016/j.annonc.2020.11.014
pubmed: 33549387
Goldschmidt H, Baertsch M-A, Schlenzka J, Becker N, Habermehl C, Hielscher T, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021;35(4):1134–44.
doi: 10.1038/s41375-020-0948-0
pubmed: 32694619
Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3(7):e340–51.
doi: 10.1016/S2352-3026(16)30049-7
pubmed: 27374467
Atanackovic D, Schilling G. Second autologous transplant as salvage therapy in multiple myeloma. Br J Haematol. 2013;163(5):565–72.
doi: 10.1111/bjh.12579
pubmed: 24111632
Weaver C, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86(10):3961–9.
doi: 10.1182/blood.V86.10.3961.bloodjournal86103961
pubmed: 7579367
Alegre A, Tomás J, Martínez-Chamorro C, Gil-Fernández J, Fernández-Villalta M, Arranz R, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant. 1997;20(3):211–7.
doi: 10.1038/sj.bmt.1700867
pubmed: 9257889
Afifi S, Adel NG, Devlin S, Duck E, Vanak J, Landau H, et al. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplant. 2016;51(4):546–52.
doi: 10.1038/bmt.2015.322
pubmed: 26726942
pmcid: 7337097
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–6.
doi: 10.1182/blood-2008-08-174946
pubmed: 19363221
Micallef IN, Stiff PJ, Stadtmauer EA, Bolwell BJ, Nademanee AP, Maziarz RT, et al. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34
doi: 10.1002/ajh.23561
pubmed: 23907769
pmcid: 4295654
Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transplant. 2015;21(12):2039–51.
doi: 10.1016/j.bbmt.2015.09.016
pubmed: 26428082
pmcid: 4757494
Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, et al. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF: CY or Plerixafor for PBPC Mobilization. J Clin Apheresis. 2013. https://doi.org/10.1002/jca.21280 .
doi: 10.1002/jca.21280
pubmed: 23765597
Furundarena JR, Uranga A, Alkorta A, González C, Javier Ferreiro J, Rey M, et al. Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield. Int J Lab Hematol. 2020;42(2):170–9.
doi: 10.1111/ijlh.13142
pubmed: 31830371
Greil C, Kiote-Schmidt C, Fink G, Ihorst G, Hildenbeutel S, Bosse R, et al. Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. Leuk Lymphoma. 2017;58(8):1849–58.
doi: 10.1080/10428194.2016.1271946
pubmed: 28084849
Malard F, Mohty M. Management of patients with multiple myeloma during the COVID-19 pandemic. Lancet Haematol. 2020;7(6):e435–7.
doi: 10.1016/S2352-3026(20)30124-1
pubmed: 32353254
pmcid: 7185930